Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

InspireMD (NSPR) EBIT (2016 - 2025)

InspireMD (NSPR) has 16 years of EBIT data on record, last reported at -$13.1 million in Q3 2025.

  • For Q3 2025, EBIT fell 54.23% year-over-year to -$13.1 million; the TTM value through Sep 2025 reached -$46.9 million, down 56.62%, while the annual FY2024 figure was -$33.5 million, 58.46% down from the prior year.
  • EBIT reached -$13.1 million in Q3 2025 per NSPR's latest filing, roughly flat from -$13.0 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.3 million in Q1 2021 and bottomed at -$13.1 million in Q3 2025.
  • Average EBIT over 5 years is -$6.6 million, with a median of -$5.3 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 83.64% in 2021, then rose 2.34% in 2023.
  • A 5-year view of EBIT shows it stood at -$3.9 million in 2021, then dropped by 25.57% to -$4.9 million in 2022, then dropped by 17.67% to -$5.8 million in 2023, then crashed by 61.28% to -$9.4 million in 2024, then plummeted by 39.33% to -$13.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$13.1 million in Q3 2025, -$13.0 million in Q2 2025, and -$11.5 million in Q1 2025.